RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals
First, do no harm by withdrawing treatment
Torres, H. A., Vauthey, J-N., Economides, M. P., Mahale, P., & Kaseb, A. (2016). Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. Journal of Hepatology, 65(4), 862-864. https://doi.org/10.1016/j.jhep.2016.05.034
We read with interest the article by Reig et al. [ [1] ] and applaud their pharmacovigilance efforts. However, because we work in a major cancer center in the United States, we are concerned about the consequences of the authors’ assumption that the use of direct-acting antivirals (DAAs) may induce hepatocellular carcinoma (HCC) relapse. This can affect not only the already cumbersome approval of DAAs for hepatitis C virus (HCV)-infected patients with HCC but also preclude patients with other cancers or HCV-associated malignancies (e.g., non-Hodgkin lymphomas) from receiving antiviral treatment associated with improved virologic, hepatic, and oncologic outcomes [ 2 , 3 ].